<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Covidien Limited</title>
	<atom:link href="http://www.stockbloghub.com/tag/covidien-limited/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(COV) Covidien Limited &#8211; Value &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/23/cov-covidien-limited-value-zacks-rank-buy/5955</link>
		<comments>http://www.stockbloghub.com/2009/04/23/cov-covidien-limited-value-zacks-rank-buy/5955#comments</comments>
		<pubDate>Thu, 23 Apr 2009 21:36:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5955</guid>
		<description><![CDATA[Covidien Limited (COV), the medical device manufacturer, has surprised on estimates 7 quarters in a row. Will it do it again on Apr 30? Second quarter estimates have risen by nearly 17% in the last 3 months. COV has a forward P/E of 11.35. Company Description Covidien manufactures medical devices, pharmaceutical products and medical supplies. The company has offices in 59 countries and customers in more than 140 countries. First Quarter Produces Earnings Surprise On Jan 26, Covidien reported first-quarter 2009 results that beat Wall Street estimates by 8.57%. The company reported 76 cents compared to analysts&#8217; estimates of 70 cents per share. During a difficult economic period, sales still rose 6% to $2.5 billion from $2.3 billion in the year ago period. Pharmaceutical products were especially strong in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/23/cov-covidien-limited-value-zacks-rank-buy/5955/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

